Thermo Fisher Scientific Inc.: Form 10-Q for the period ended Jul 1, 2023
Filed with the SEC on Aug 4, 2023 and accepted by EDGAR at Aug 4, 2023, 11:06 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-07-01. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-04-02 to 2023-07-01 | $10.69bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2023-01-01 to 2023-07-01 | $21.40bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months2023-04-02 to 2023-07-01 | $345.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2023-01-01 to 2023-07-01 | $691.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2023-04-02 to 2023-07-01 | $2.15bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2023-01-01 to 2023-07-01 | $4.26bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2023-04-02 to 2023-07-01 | $1.58bn | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2023-01-01 to 2023-07-01 | $3.14bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2023-04-02 to 2023-07-01 | $326.0m | us-gaap:InterestExpense |
| Interest expense | 6 months2023-01-01 to 2023-07-01 | $626.0m | us-gaap:InterestExpense |
| Income tax | 3 months2023-04-02 to 2023-07-01 | $52.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2023-01-01 to 2023-07-01 | $98.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-04-02 to 2023-07-01 | $1.36bn | us-gaap:ProfitLoss |
| Net income | 6 months2023-01-01 to 2023-07-01 | $2.65bn | us-gaap:ProfitLoss |
| Diluted EPS | 3 months2023-04-02 to 2023-07-01 | $3.51 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2023-01-01 to 2023-07-01 | $6.83 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-04-02 to 2023-07-01 | $3.53 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2023-01-01 to 2023-07-01 | $6.86 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-04-02 to 2023-07-01 | 388,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2023-01-01 to 2023-07-01 | 388,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2023-01-01 to 2023-07-01 | $2.27bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2023-01-01 to 2023-07-01 | $742.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 6 months2023-01-01 to 2023-07-01 | $252.0m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 6 months2023-01-01 to 2023-07-01 | $3.00bn | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2023-07-01 | $3.13bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-07-01 | $20.00bn | us-gaap:AssetsCurrent |
| Total assets | At period end2023-07-01 | $94.11bn | us-gaap:Assets |
| Current liabilities | At period end2023-07-01 | $14.11bn | us-gaap:LiabilitiesCurrent |
| Long-term debt | At period end2023-07-01 | $33.81bn | us-gaap:LongTermDebt |
| Current portion of debt | At period end2023-07-01 | $4.81bn | us-gaap:DebtCurrent |
| Shareholders' equity | At period end2023-07-01 | $43.75bn | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2023-07-01 | 385,949,773 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0000097745-23-000059. Last ingested by Listed: Nov 14, 2026, 12:05 ET. Listed shows no prices and gives no investment advice.